Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma

Canine histiocytic sarcoma (CHS) is a malignant tumor derived from macrophages and dendritic cells. Since effective chemotherapy is needed for CHS cases, we conducted this prospective study to evaluate the efficacy and adverse events of vincristine treatment as a rescue therapy for this disease. We...

Full description

Saved in:
Bibliographic Details
Published inJournal of Veterinary Medical Science Vol. 86; no. 10; pp. 1100 - 1104
Main Authors SAKUMA, Hiroki, TANI, Akiyoshi, GOTO-KOSHINO, Yuko, OHMI, Aki, TSUJIMOTO, Hajime, TOMIYASU, Hirotaka
Format Journal Article
LanguageEnglish
Published Japan JAPANESE SOCIETY OF VETERINARY SCIENCE 2024
Japan Science and Technology Agency
The Japanese Society of Veterinary Science
Subjects
Chemotherapy
Dendritic cells
Disease resistance
dog
histiocytic sarcoma
Internal Medicine
Macrophages
Remission
Sarcoma
Thrombocytopenia
Vincristine
histiocytic sarcoma
vincristine
chemotherapy
dog
Online AccessGet full text

Cover

More Information
Summary:Canine histiocytic sarcoma (CHS) is a malignant tumor derived from macrophages and dendritic cells. Since effective chemotherapy is needed for CHS cases, we conducted this prospective study to evaluate the efficacy and adverse events of vincristine treatment as a rescue therapy for this disease. We administered vincristine to nine CHS cases that acquired resistance to lomustine or nimustine. Complete remission was achieved in one dog, partial remission in two dogs, stable disease in five dogs, and progressive disease in one dog. The median progression-free survival was 21 days (range: 7–71 days). Severe adverse effect was observed in one dog (Grade 3 thrombocytopenia). It is essential to establish novel effective treatments for CHS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0916-7250
1347-7439
1347-7439
DOI:10.1292/jvms.24-0218